Squawk Box: The Valeant Exit
A Rare Public Admission of Error
A Squawk Box panel segment — third-party coverage, not an interview — dissecting Pershing Square's complete exit from Valeant at a loss of roughly $4 billion: whether the wound is Ackman-specific or a broader statement about hedge-fund activism. Ackman himself does not appear; the segment's archival value is exactly that — the market conducting its own autopsy of the valley's deepest cut in real time. The 2016 annual report provides Ackman's own account.
“the thing that everybody's asking today is this really unique to Bill Amman because he really did go out on a limb for this company or is this a broader issue about how hedge funds are investing”
Summary
This segment captures the market conversation on the day Pershing Square's exit from Valeant became public. The hosts frame the exit as a defining moment not only for Bill Ackman but for the broader hedge-fund culture of concentrated, high-conviction investing. They acknowledge that Ackman had gone "out on a limb" for Valeant, joined its board, and defended the company through the Philidor specialty-pharmacy scandal. The discussion treats the exit as a signal: it removes a potential turnaround catalyst and raises questions about Valeant's ability to fund more than $30 billion in debt, sustain its pricing model, and remain independent. The tone is analytical rather than celebratory, balancing the schadenfreude circulating in New York with recognition that Valeant's collapse was a compound failure of strategy and capital structure rather than a single bad call.
On Pershing Square's exit signal:
"their exit today does question the future growth of the company and the ability to turn the story around"
On unsustainable pricing and M&A:
"the pricing is an issue that was something that was just not sustainable at the company the m&a activity was also just simply not sustainable"
On debt-fueled expansion:
"the company really built itself up through a series of Acquisitions in a very short period of time which landed them with over $30 billion in debt"
Full Text
Machine-generated transcript (ASR); minor transcription errors may exist. Speaker turns and paragraphing restored editorially — words unchanged.
Interviewer:
the thing that everybody's asking today is this really unique to Bill Amman because he really did go out on a limb for this company or is this a broader issue about how hedge funds are investing
Guest:
yeah I think it definitely speaks to the broader issues that we're seeing at Valiant but certainly as you mentioned Bill Atman and Persian Square have really been a champion for the company the joining of several of purging Square members to Valiant board was sort of seen as a signal that there could be a turnaround at the company and that was definitely a positive during all of the struggles that the company had been facing about a year ago uh but certainly you know their exit today does question the future growth of the company and the ability to turn the story around there's a lot of shod and Freer going around New York City I think today about Bill Amman and we want to recognize that I mean a lot of people are rooting against him it's tough you make mistakes it happens at the same time he was deeply involved in this company when it ran into troubles
Interviewer:
was the fundamental problem really in their structure that they would buy cheap drugs who have been around and just jack up the prices or did it was it a more fundamental issue within the company
Guest:
yes so definitely the pricing is an issue that was something that was just not sustainable at the company the m&a activity was also just simply not sustainable the company really built itself up through a series of Acquisitions in a very short period of time which landed them with over $30 billion in debt uh after the fil issue which was the Specialty Pharmacy that bant had been using to prop up prices after that whole debacle sort of settled out and Bill Amman came out and said the story can turn around lawsuits have happened this isn't the end for the company he had actually claimed a $448 price target for the company and now you know we're trading around $11 per share at best so that certainly indicates his confidence previous to the news that we received yesterday
Interviewer:
yeah exactly and we got the news yesterday it didn't help the stock one bit as we said the the the shares are down what's the future of this company I mean there had been some good news actually coming out of it can it survive on its own or is it really an acquisition candidate
Guest:
yeah it's sort of one step forward two steps back with this company you know we see a drug approval and then the next day we see a delay with another approval uh and we saw early last week that the company did successfully sell some of its assets which has been part of the plan which allowed them to pay down $1.1 billion in debt but at the same time they announced a restructuring to their financing which gave some pause in terms of the actual growth opportunities after the company really just reported and said that they would be able to meet Debt Pay down so there is a question of growth and looking at some of the key franchises we see lagging volume and still negative price pressure
Key Themes
- Volatility vs. Permanent Loss of Capital — the stock's fall from a $448 price target to ~$11 illustrates the gap between price decline and permanent impairment of the business model
- Inversion and Thesis Stress-Testing — the segment asks whether the problem was simply pricing or a deeper structural failure that should have been stress-tested earlier
- Capital Allocation Discipline — the $30 billion debt load and serial acquisitions are treated as the unsustainable engine of Valeant's growth
- The Right CEO — Pearson's strategy is implicitly on trial; the board exit removes a management-aligned catalyst
- Avoiding Extrinsic Risks — the pricing model and specialty-pharmacy channel depended on political and payer tolerance outside management's control
- J. Michael Pearson — the Valeant CEO whose capital-allocation and pricing decisions are at the center of the autopsy
Context & Significance
This segment sits in Act III, the valley, at the moment Pershing Square's Valeant loss crystallizes into public fact. The speakers are not processing the exit with the benefit of hindsight; they are reacting to a live wound. Their focus on Ackman's public commitment — board membership, a $448 price target, prior defense of the company — captures the mindset of an investor whose identity had become entangled with a single position. The honest retrospective is that the segment itself documents how hard it was to separate the man from the stock even as the stock collapsed: the questions keep returning to whether Ackman's mistake was unique or systemic, as if the answer would determine whether the rest of the industry should feel safe.
The corpus also records a debate that was unresolved in real time. One speaker lands on pricing and unsustainable M&A as the core failure; the other sees a company that keeps reporting operational progress while the financing and growth trajectory deteriorate. Neither speaker knows how the story ends, and neither engages in the cheap moralizing that would arrive later. What the transcript preserves is the confusion of a valley moment: a roughly $4 billion loss announced not by Ackman himself but by the market's attempt to make sense of it while the price still moved.
Read against the 2016 annual report, this segment is the external mirror to Ackman's internal reckoning. The report would later formalize the lessons — volatility versus permanent loss, inversion, the Eight Commandments — but here those lessons are still being discovered in public.